IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F16%3A00472725" target="_blank" >RIV/61388971:_____/16:00472725 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1080/2162402X.2015.1102829" target="_blank" >http://dx.doi.org/10.1080/2162402X.2015.1102829</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/2162402X.2015.1102829" target="_blank" >10.1080/2162402X.2015.1102829</a>

Result language
angličtina
Original language name
IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?
Original language description
he in vivo biological activity of IL-2 can be dramatically increased by complexing with anti-IL-2 mAb. Moreover, IL-2/anti-IL-2 mAb immunocomplexes selectively stimulate different subsets of immune cells, depending on the clone of anti-IL-2 mAb that is used. Thus, IL-2/S4B6 mAb complexes strongly stimulate CD122(high) populations, namely NK and memory CD8(+) T cells. They also intermediately stimulate T-reg cells. Conversely, IL-2/JES6.1 mAb immunocomplexes have no stimulatory activity for CD122(high) populations. However, they potently and highly selectively stimulate CD25(+) cells (i.e., T-reg and activated T cells). IL-2/S4B6 mAb immunocomplexes have also been shown to possess antitumor activity in various mouse tumor models.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EE - Microbiology, virology
OECD FORD branch
—

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)